Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
NCT02910999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 868
Last updated 2024-05-13
Summary
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-09
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- Germany
Study Locations
More Related Trials
-
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
NCT05034926 ·Status: COMPLETED
-
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
NCT04794010 ·Status: ACTIVE_NOT_RECRUITING
-
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
NCT03048136 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
NCT01642004 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
NCT05500092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
NCT01673867 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
NCT06169956 ·Status: RECRUITING
-
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
NCT05161325 ·Status: ACTIVE_NOT_RECRUITING
-
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
NCT03090737 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00923312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
NCT07141563 ·Status: COMPLETED
-
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
NCT02350764 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
NCT02659059 ·Status: COMPLETED ·Phase: PHASE2
-
Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program
NCT02933346 ·Status: COMPLETED
-
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
NCT04500535 ·Status: COMPLETED
-
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
NCT04205552 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
NCT05543629 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133 ·Status: TERMINATED ·Phase: PHASE2
-
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology
NCT04046614 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
NCT02409368 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
NCT07024862 ·Status: ACTIVE_NOT_RECRUITING
-
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02869789 ·Status: COMPLETED ·Phase: PHASE4
-
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
NCT02847728 ·Status: COMPLETED
-
BMS-986012 in Relapsed/Refractory SCLC
NCT02247349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2